TP53 and dysplasia: Moreover, the ‘two-hit’ events on TP53 are dominant in the dysplasia and carcinoma samples from the 45 ESCC patients, but rare in the dysplasia samples from the 13 tumor-free patients, suggesting that the full inactivation of TP53 is essential in promoting the development of ESCC.